GSA Capital Partners’s Astria Therapeutics ATXS Stock Holding History

GSA Capital Partners’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-22,062	Closed	-$289K	–	1703
2025 Q4	$289K	Buy	+22,062	New	+$264K	0.02%	1183
2025 Q3	–	Sell	-30,928	Closed	-$166K	–	1644
2025 Q2	$166K	Sell	30,928 -36,246	-54%	-$176K	0.01%	1544
2025 Q1	$359K	Buy	+67,174	New	+$470K	0.03%	1028
2021 Q4	–	Sell	-24,996	Closed	-$221K	–	1403
2021 Q3	$221K	Buy	+24,996	New	+$239K	0.02%	1185
2021 Q1	–	Sell	-7,847	Closed	-$101K	–	1091
2020 Q4	$101K	Buy	+7,847	New	+$140K	0.02%	1096

GSA Capital Partners's ATXS Position: Q1 2026 in Review

GSA Capital Partners sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 22,062 shares — an estimated $289K sold.

GSA Capital Partners first reported a position in ATXS in Q4 2020 and held it in 5 quarters. The position peaked at $359K in Q1 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

GSA Capital Partners reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 22,062 Astria Therapeutics shares in Q1 2026, an estimated $289K.
GSA Capital Partners first reported a position in Astria Therapeutics in Q4 2020 and held it in 5 quarters.
GSA Capital Partners's Astria Therapeutics position peaked at $359K in Q1 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.